NKGen Biotech (NYSE:NKGN) Shares Down 2.9%

NKGen Biotech, Inc. (NYSE:NKGN) shares dropped 2.9% on Wednesday . The company traded as low as $1.15 and last traded at $1.17. Approximately 70,593 shares traded hands during trading, a decline of 97% from the average daily volume of 2,060,171 shares. The stock had previously closed at $1.20.

NKGen Biotech Stock Performance

The stock’s 50 day simple moving average is $1.34 and its two-hundred day simple moving average is $1.67.

NKGen Biotech (NYSE:NKGN) last issued its earnings results on Monday, May 20th. The company reported ($0.25) EPS for the quarter.

Institutional Investors Weigh In On NKGen Biotech

An institutional investor recently bought a new position in NKGen Biotech stock. Sequoia Financial Advisors LLC purchased a new stake in NKGen Biotech, Inc. (NYSE:NKGN) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 16,000 shares of the company’s stock, valued at approximately $30,000. Sequoia Financial Advisors LLC owned about 0.07% of NKGen Biotech as of its most recent SEC filing. Institutional investors own 76.17% of the company’s stock.

NKGen Biotech Company Profile

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.